Here are the 10-K annual reports from Xenetic Biosciences, Inc. (XBIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIO filings page.
Xenetic Biosciences, Inc. filed an amendment to its annual report to add the Part III sections on directors, executive compensation, ownership and related-party transactions, and to update the cover-page share count to 2,291,056 common shares as of April 17, 2026. The filing details the board’s committee structure and independence, insider trading and related-party policies, and a single named executive officer, Interim CEO and CFO James Parslow. His 2025 total compensation was $536,027, including a $100,000 retention bonus and benefits, and he holds multiple option grants with exercise prices ranging from $3.88 to $548.40 per share. Pay-versus-performance tables show Compensation Actually Paid to the CEO moving broadly in line with total shareholder return and net losses, including a 2025 net loss of $2,680,860 and a total shareholder return value of $76.11 on a hypothetical $100 investment. The amendment also discloses 2025 audit and audit-related fees of $208,000, equity plan overhang of 115,622 options outstanding with 137,985 shares remaining available for issuance, and principal stockholders such as Renaissance Technologies LLC with 178,509 shares, or 7.8% of the common stock.
Xenetic Biosciences is an early-stage immuno-oncology company focused on DNase technology to improve treatment of difficult solid tumors, initially pancreatic and colorectal cancers. The approach targets neutrophil extracellular traps that contribute to tumor growth and resistance to chemotherapy, radiotherapy and immunotherapy.
The company is advancing a systemic DNase I program toward first-in-human studies and exploring DNase‑armored CAR T cells to improve cell therapy performance in solid tumors. Development is executed largely through external partners and academic collaborations, including Scripps Research, the University of Virginia, Catalent and PeriNess.
Xenetic has begun a formal strategic review, considering options such as a sale, asset sale or reverse merger, with outcomes that could significantly alter ownership. The business remains unprofitable, expects substantial additional funding needs, and currently generates modest royalties from a PolyXen out‑license to Takeda while prioritizing DNase over legacy platforms.